文献速递头颈外科

多专业术前评估与信息告知对头颈癌患者术后结局的关联

Association of Multiprofessional Preoperative Assessment and Information for Patients With Head and Neck Cancer With Postoperative Outcomes.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

这项回顾性单中心病例对照研究纳入161例接受复杂肿瘤性头颈癌手术的患者,比较实施多专业术前评估与信息日(MUPAID)前后的术后结局。结果显示,干预组严重局部和全身并发症更少(Clavien-Dindo III-V级34.6% vs 52.5%),中位住院时间更短(12天 vs 16天),中位每例费用更低(50 848美元 vs 69 602美元)。

要点

  • MUPAID与复杂头颈癌手术后严重并发症比例降低相关(34.6% vs 52.5%)。
  • MUPAID与中位住院时间缩短相关(12天 vs 16天)。
  • MUPAID与中位每例费用降低相关(50 848美元 vs 69 602美元)。

核心结论

  • 这项病例对照研究结果提示,对接受复杂肿瘤性头颈癌手术的患者实施MUPAID与住院时间缩短、每例费用降低及并发症严重程度降低相关。

研究设计与样本

  • 回顾性单中心病例对照研究,在三级转诊头颈抗癌中心/大学癌症研究所开展,比较2012年1月至2018年7月间接受复杂肿瘤手术的头颈癌患者实施机构MUPAID前后(对照组与干预组)的结局。
  • 研究纳入161例患者,干预组81例(女性25例,30.9%),对照组80例(女性18例,22.5%);干预组为2015年2月起参与MUPAID的患者。
  • 干预组由多专业团队评估,并提供关于手术及其功能、社会、经济、心理影响以及术后护理、康复和随访期的结构化和全面信息;对照组通过手术操作代码筛选。
  • 数据分析于2019年至2020年间进行。

主要发现

  • 干预组严重局部和全身并发症(Clavien-Dindo评分III-V级)比例为34.6%,对照组为52.5%(差异比例-0.179;95%CI,-0.33至-0.03)。
  • 干预组中位住院时间为12天(IQR,10-16天),对照组为16天(IQR,11-20天);效应量0.482(95%CI Cohen d,0.152-0.812)。
  • 干预组中位每例费用为50 848美元(IQR,42 510-63 479美元),对照组为69 602美元(IQR,45 631-96 280美元);效应量0.534(95%CI Cohen d,0.22-0.85)。
  • 两组在社会人口学、疾病和手术特征方面无相关差异。

临床怎么用

  • 作者认为,这些结果在患者层面有潜力减轻个体治疗负担,在机构和医疗系统层面有潜力显著优化手术结局和财务方面。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Multidisciplinary perioperative assessment for patients undergoing complex oncologic head and neck cancer (HNC) surgery is widely implemented. However, to our knowledge, the association of multiprofessional preoperative assessment, information, and briefing with postoperative outcomes has not been evaluated. OBJECTIVE: To compare postoperative complications, length of hospital stay (LOS), readmissions, mortality, and costs per case among patients undergoing complex oncologic HNC surgery before and after the implementation of a comprehensive preoperative multiprofessional assessment and information day (MUPAID). DESIGN, SETTING, AND PARTICIPANTS: This retrospective, single-center case-control study was conducted at a tertiary referral head and neck anticancer center/university cancer institute and compared patients with HNC who were undergoing complex oncological surgeries between January 2012 and July 2018 before (control group) and after (intervention group) implementation of the institutional MUPAID. Data analysis was conducted between 2019 and 2020. The intervention group comprised patients who participated in the MUPAID beginning in February 2015. These patients were assessed by a multiprofessional team and provided with structured and comprehensive information on the surgical procedure and its functional, social, financial, and psychological effects, as well as the postoperative care, rehabilitation, and follow-up period. Patients in the control group had also undergone complex oncologic HNC surgery and were selected through surgical procedure codes. MAIN OUTCOMES AND MEASURES: The end points were postoperative rate and severity of complications, LOS, readmissions, mortality, and costs per case. RESULTS: The study included 161 patients, 81 in the intervention (25 women [30.9%]) and 80 in the control group (18 women [22.5%]). The groups showed no relevant differences in sociodemographic, disease, and procedural characteristics. The intervention cohort presented with fewer major local and systemic complications (Clavien-Dindo score, III-V: 34.6% vs 52.5%; difference proportion, -0.179; 95% CI, -0.33 to -0.03), shorter median LOS (12 days [IQR, 10-16 days] vs 16 days [IQR, 11-20] days; effect size, 0.482; 95% CI Cohen d, 0.152-0.812) and decreased median charge per case ($50 848 [IQR, $42 510-$63 479] vs $69 602 [IQR, $45 631-$96 280]; effect size, 0.534; 95% CI Cohen d, 0.22-0.85). CONCLUSIONS AND RELEVANCE: The results of this case-control study suggest that MUPAID for patients who are undergoing complex oncologic HNC surgery is associated with shortened LOS and costs per case as well as decreased complications severity. These results are promising on a patient level in the potential to minimize individual treatment burden, as well as on an institutional and health care system level in the potential significant optimization of surgical outcomes and financial aspects.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Schmid M, Giger R, Nisa L, et al. Association of Multiprofessional Preoperative Assessment and Information for Patients With Head and Neck Cancer With Postoperative Outcomes. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 35050322. doi:10.1001/jamaoto.2021.4048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。